Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.

Also called NCT02390102

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 117 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02390102
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02390102. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (actual); primary completion 2015-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement
Acronym
EPICURE
Condition
Anemia
Condition
Aortic Stenosis
Intervention (Drug)
Erythropoietin
Intervention (Drug)
Placebo
Lead sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (class: other)

Record details

Record id
cardio:ct-nct02390102
Content hash
8fb466f1675da2e1007cb51f7da5a8fc99642d678114363267aed4de72cf4515